Organogenesis Holdings Inc.
Moat Score — Organogenesis Holdings Inc.
Total Moat Score
9 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | A broad regenerative-medicine portfolio spanning three distinct FDA regulatory pathways (PMA, 510(k), and Section 361 HCT/P) gives Organogenesis diversified intellectual/regulatory assets, though many individual products face direct substitute competition. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Despite a strong 76% gross margin, net income was just $0.9 million on $482.0 million of revenue in FY2024, showing no structural cost advantage over competitors once sales force and R&D spend are included. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Reimbursement and payer coverage decisions drive much of the demand for Organogenesis's wound-care and surgical products, limiting independent pricing power regardless of clinical efficacy. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Tissue and wound-care products have no network effect; one clinician's or hospital's adoption does not make the product more valuable to the next customer. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Established clinician relationships, reimbursement coding familiarity, and a 256-person direct sales force create some switching friction, but many competing tissue products can be substituted at the point of care. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The company itself discloses that its Section 361 HCT/P segment has structurally low barriers to entry, allowing many smaller competitors to enter without PMA or 510(k) burdens. |